Net Promoter Score

Teva and Medincell’s once-monthly olanzapine injection shows promise in trials, potentially freeing patients from burdensome post-injection observation.

The mobile health firm now reaches 25 states with its tech-driven model, aiming to close care gaps and answer federal critics of in-home assessments.

BeneCard PBF wins a prestigious third consecutive customer service award, but a deeper look reveals a complex story behind the celebrated metrics.

As global tech firms flock to Utah's booming Silicon Slopes, AssureSoft's presence signals a major evolution in nearshoring beyond cost-cutting to strategic AI partnership.

eDreams ODIGEO is cancelling millions of shares, powered by its Prime subscription model. But can it sustain aggressive buybacks while chasing growth?

After its RELYVRIO setback, Amylyx's next-gen ALS drug AMX0114 clears a key safety hurdle. Is this the strategic pivot investors have been waiting for?